Antipodes Partners’s Johnson Controls International JCI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$139K Sell
1,058
-690
-39% -$89.1K ﹤0.01% 88
2025
Q4
$209K Sell
1,748
-718,892
-100% -$82.5M ﹤0.01% 84
2025
Q3
$79.2M Sell
720,640
-551,132
-43% -$58.9M 1.78% 24
2025
Q2
$134M Buy
1,271,772
+138,092
+12% +$12.7M 4.17% 9
2025
Q1
$90.8M Sell
1,133,680
-81,681
-7% -$6.72M 2.84% 14
2024
Q4
$95.9M Buy
1,215,361
+1,215,051
+391,952% +$97.5M 3.33% 11
2024
Q3
$24.1K Sell
310
-791
-72% -$55.5K ﹤0.01% 78
2024
Q2
$73.2K Sell
1,101
-359,867
-100% -$24.2M ﹤0.01% 61
2024
Q1
$23.6M Buy
360,968
+107,109
+42% +$6.24M 0.75% 32
2023
Q4
$14.6M Buy
253,859
+119,844
+89% +$6.29M 0.46% 36
2023
Q3
$7.13M Buy
134,015
+132,358
+7,988% +$8.17M 0.23% 38
2023
Q2
$112K Buy
1,657
+227
+16% +$14K ﹤0.01% 48
2023
Q1
$86K Buy
+1,430
New +$91.6K ﹤0.01% 48

Other funds holding JCI

Antipodes Partners's JCI Position: Q1 2026 in Review

Antipodes Partners reduced its Johnson Controls International (JCI) stake by 39% in Q1 2026, selling an estimated $89.1K and leaving 1,058 shares worth $139K. The position accounts for ﹤0.01% of the portfolio, ranked #88.

Antipodes Partners first reported a position in JCI in Q1 2023 and has held it in 13 quarters since. The position peaked at $134M in Q2 2025. 1,556 funds tracked by Wall St. Rank hold JCI as of Q1 2026.

  • Antipodes Partners held 1,058 shares of Johnson Controls International worth $139K as of Q1 2026.
  • Antipodes Partners sold 690 Johnson Controls International shares in Q1 2026, an estimated $89.1K.
  • Johnson Controls International made up ﹤0.01% of Antipodes Partners's portfolio in Q1 2026, its #88 holding.
  • Antipodes Partners first reported a position in Johnson Controls International in Q1 2023 and has held it in 13 quarters since.
  • Antipodes Partners's Johnson Controls International position peaked at $134M in Q2 2025.
  • 1,556 funds tracked by Wall St. Rank held Johnson Controls International as of Q1 2026.

Based on Antipodes Partners's 13F filing for Q1 2026, filed 5 May 2026.